News & Updates

In a prespecified analysis of the DELIVER* study, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the rate of total** heart failure (HF) events or cardiovascular (CV) deaths in HF patients with mildly reduced or preserved ejection fraction (HFmrEF or HFpEF).

In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.

Treatment with S-1, an oral fluoropyrimidine formulation similar to capecitabine, plus oxaliplatin (SOX) results in substantial improvements in overall response rate relative to capecitabine plus oxaliplatin (CapeOx) in patients with metastatic colorectal cancer, according to a Philippines study presented at the recent ESMO GI 2023.

In the secondary analysis of the NAMSAL and ADVANCE trials, first-line treatment with dolutegravir (DTG) was associated with significantly higher risks of treatment-emergent hypertension in people living with HIV (PLWH), especially in combination with tenofovir alafenamide (TAF).

Modified-dose regimens of nirmatrelvir-ritonavir are well tolerated and effective in COVID-19 patients with advanced chronic kidney disease (CKD), including those on dialysis, a study by the Chinese University of Hong Kong (CUHK) has shown.

Individuals with metabolic syndrome (MetS) have a heightened risk of incident lung cancer, with the risk increase especially pronounced in those with a higher number of metabolic abnormalities and in women, according to a study.